Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus

NCT05664750 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

675

Enrollment

INDUSTRY

Sponsor class

Conditions

Tetanus

Interventions

DRUG: TNM002
DRUG: Human tetanus immunoglobulin (HTIG)

Sponsor

Zhuhai Trinomab Pharmaceutical Co., Ltd.